AzTrials
AzTrials

AnaesthesiaNCT02163486

Comparison Between the I-gel and the LMA-Unique

A study testing Group U (UNIQUE) and I-GEL in people with Anaesthesia, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Airway management is one of the basic topics in anesthetic practice. Use of endotracheal intubation and face mask are standard methods to maintain an open airway widely adopted for many years. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Anaesthesia
What is being tested?
Group U (UNIQUE) and I-GEL
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
103 participants
Where
1 siteTurkey (Türkiye)
Study dates
Dec 2010to Mar 2011
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ASA I-II
  • 18-65 years

Who cannot join

  • Any neck or upper respiratory pathology
  • Those at risk of gastric content regurgitation/aspiration (previous upper gastro-intestina system surgery, known hiatus hernia, gastroesophageal reflux, history of peptic ulcer, full stomach, pregnancy)
  • Possibility of and those with history of difficult intubation (history of impossible intubation, Mallampati classification 3-4, sterno mental distance less than 12 cm, thyromental distance less than 6 cm, head extension less than 90 degrees, mouth opening less than 1.5 cm)
  • Those with low pulmonary compliance or high airway resistance (morbid obesity, lung disease)
  • Throat pain, dysphagia and dysphonia
  • Patients with cervical disc hernia

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation

    Izmir, Narlıdere, 35320

Other trials in Turkey (Türkiye)

About this study

Official title: The Influence of Head and Neck Position On The Oropharyngeal Leak Pressure of LMA Unique ™ and I-GEL™

Airway management is one of the basic topics in anesthetic practice. Use of endotracheal intubation and face mask are standard methods to maintain an open airway widely adopted for many years. As a result of a search for more appropriate choices from the point of view of effectiveness, reliability and side effects, supraglottic airway devices (SGAD) have been developed.

SGAD's are used for thyroid surgery, ear surgery, carotid endarterectomy, adenotonsillectomy and laser pharyngoplasty, which require a variety of head-neck positions. Changing the head and neck position leads to changes in the shape of the pharynx, which causes variation in the cuff pressure and oropharyngeal leak pressure. Oropharyngeal leak pressure values play a determining role in protecting the airway from high cuff pressure. Additionally it shows that the laryngeal mask is correctly placed and is a sign of the effectiveness of positive pressure ventilation. During surgery head-neck and trunk position may change. As a result there is a need for research evaluating the effect of head and neck position on oropharyngeal leak pressure during SGAD use.

Read more

AIM

The aim of this study is to compare the effect of different head and neck positions on the oropharyngeal leak pressure in LMA-Unique and I-Gel applications. Additionally the placement duration, ease and success of these two supraglottic airway devices will be compared.

Read the detailed description

This prospective, randomized, double-blind study will receive permission from the Local Research Ethics Committee and after obtaining patients' informed consent, 103 patients with American society of anesthesiologists (ASA) classification group I-II, between 18-65 years, undergoing elective surgery with indications for supraglottic airway device placement were included in the study.

All patients preoperatively evaluated and ASA and Mallampati classification recorded.

All SGAD's inserted by the same experienced researcher. After placement of laryngeal mask, to standardize postoperative pharyngeal morbidity, cuff pressure (cuff pressure manometer, Ruch, Germany) was monitored.

EXCLUSION CRITERIA:

  • Any neck or upper respiratory pathology
  • Those at risk of gastric content regurgitation/aspiration (previous upper Gastro-intestinal surgery, known hiatus hernia, Gastroesophageal reflux, history of peptic ulcer, full stomach, pregnancy)
  • Possibility of and those with history of difficult intubation (history of impossible intubation, Mallampati classification 3-4, sterno mental distance less than 12 cm, thyromental distance less than 6 cm, head extension less than 90 degrees, mouth opening less than 1.5 cm)
  • Those with low pulmonary compliance or high airway resistance (morbid obesity, lung disease)
  • Throat pain, dysphagia and dysphonia
  • Patients with cervical disc hernia

Patients taken to the operating room were given standard monitoring before anesthesia induction. Patients were preoxygenated with 6 L/min oxygen for 3 minutes through a face mask.

Anesthesia induction was provided by 0.02 mg/kg midazolam, 1-2 mcg/kg fentanyl, 1.5-2 mg/kg propofol and 0.5 mg/kg rocuronium.

All patients have neuromuscular junction monitoring (TOF-GUARD, Biometer International A.S. DENMARK) and when TOF is zero SGAD was inserted with the standard method according to the firm's recommendations.

During SGAD placement, if necessary additional dose of 0.5 mg/kg propofol was given depending on patient reaction. During this procedure cases were ventilated with 100% oxygen though a mask.

STUDY GROUPS:

Group U (UNIQUE): LMA- UNIQUE, inserted according to described standard method

Group I (I-GEL ) : I-GEL, inserted with standard technique according to users manual

For LMA-U the laryngeal mask cuff was inflated so that cuff pressure is less than 60 cm H2O with leak preventive volume. After the operation before the laryngeal mask was removed the cuff pressure was measured again and recorded.

To check SGAD placement bilateral chest movement was observed and capnography be used to confirm a square wave shape. After SGAD was placed oropharyngeal leak test was completed. Oropharyngeal leak pressure were tested in both groups first in neutral head position, then at maximum extension and with head at maximum rotation to the right. In every position the leak measurement was made 60 seconds after position is changed. In order to prevent the SGAD from being seen by the researcher during the tests the patient's head was covered.

Oropharyngeal leak pressure was measured with the ring system expiratory valve closed and 4 L/min flow. To prevent exposure of the lungs to barotrauma, when peak airway pressure reaches 40 cm H2O the expiratory valve was opened .

Leak pressure was evaluated in two ways;

  1. The stethoscope is placed above the patient's left thyroid part of the trachea and the sound of a leak is listened for
  2. Checked when the aneroid manometer is held steady (manometer stability test)

When the sound of the leak is heard, the pressure on the manometer were recorded separately in both situations.

Anesthesia was maintained with 5% O2/air mix with 1.5-2.5% sevoflurane. Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), and heart rate (HR) values were measured and recorded immediately before anesthesia induction, immediately before airway device placement and at 1, 2, and 3 minutes after airway placement is checked. The time for successful placement (duration from mouth opening to first successful ventilation), number of attempts, and ease of placement were recorded.

Ease of insertion:

  1. no reaction
  2. straining, retching
  3. alternative airway management

The Mallampati score, type of supraglottic airway device, type of operation and total duration of anesthesia were recorded. Any problems occurring during head and neck positions was noted.

The cuff pressure was measured after surgery while the patient is still in deep anesthesia.

When the patient is conscious the SGAD was removed and the duration of use was recorded (time from insertion to removal).

After the SGAD is removed the presence of blood was evaluated

  1. no blood
  2. trace amounts of blood
  3. definite amount of blood

The patients throat pain, voice loss and difficulty swallowing were evaluated when leaving the recovery room and by telephone 24 hours later by a researcher blind to the insertion technique. To evaluate throat pain the VAS 10 (verbal analogue scale) was used

EXPULSION CRITERIA:

  • Oxygen saturation by pulse oximetry values falling by 90% during airway insertion
  • Cases developing laryngospasm
  • Cases with incomplete records
Conditions
Anaesthesia
Being tested
Group U (UNIQUE), I-GEL
Keywords
I-gel, oropharyngeal leak pressure, head position

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Group U (UNIQUE)Device

    Also called Laryngeal Mask Airway-Unique, Teleflex, The Laryngeal Mask Company Limited, Singapore .

    Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.

  • I-GELDevice

    Also called Group I (I-GEL): I-GEL

    Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.

    I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc

Study groups in NCT02163486
Study groupRoleWhat they receive
Group U (UNIQUE)Active comparatorGroup LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
Receives: Device: Group U (UNIQUE)
Group I (I-GEL ): Group I-GELExperimentalGroup I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For > 90 kg no.5. I-GEL
Receives: Device: I-GEL

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Oropharyngeal Leak Pressure

    The aim of this study is to compare the effect of different head and neck positions on the oropharyngeal leak pressure in LMA-Unique and I-Gel applications. Head and neck positions are limited to neutral, extension and right laterally deviated.

    Measured: Immediately after head and neck positioning is completed

Secondary outcomes (4)
  1. The Time for Successful Placement (Second)

    Duration from mouth opening to first successful ventilation, in seconds

    Measured: Baseline to first successful ventilation, in seconds

  2. Number of Attempts

    The number of attempts until succesful placement of airway device

    Measured: Baseline to first successful ventilation,

  3. Ease of Placement

    Ease of placement:

    1. no reaction
    2. straining, retching

    Measured: Baseline

  4. Incidence of Post-operative Sore Throat

    Patients were asked about the presence of sore throat - defined as the presence of constant pain in the throat, voice loss and difficulty swallowing , at postoperative 1st and 24th hours.

    Measured: at postoperative 1st and 24th hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jun 2014 (estimated)
  2. Study startDec 2010
  3. Primary completionFeb 2011
  4. Study completionMar 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
103 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02163486
Sponsor's protocol ID
10-11.1/30
Status last verified
Dec 2017
First submitted
10 Jun 2014
Last updated
19 Oct 2018
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Group U (UNIQUE) and I-GEL in people with Anaesthesia, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Oct 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Oropharyngeal Leak Pressure (time frame: Immediately after head and neck positioning is completed). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in